ProPhase Labs, Inc. Preferred Stock, Value, Issued
ProPhase Labs, Inc. (PRPH) had Preferred Stock, Value, Issued of $0 as of 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:PreferredStockValue · last filed 2026-06-01
- 2025-12-31: Preferred Stock, Value, Issued $0.00.
- 2025-09-30: Preferred Stock, Value, Issued $0.00.
- 2025-06-30: Preferred Stock, Value, Issued $0.00.
- 2025-03-31: Preferred Stock, Value, Issued $0.00.
| Period end | Preferred Stock, Value, Issued |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-06-01 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-19 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-13 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-20 |
| 2024-12-31 | $0.00 10-K · filed 2026-06-01 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-13 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-14 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-10 |
| 2023-12-31 | $0.00 10-K · filed 2025-04-01 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-13 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-11 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-12 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-29 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |